Literature DB >> 18078694

Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine.

Margaretha Stålhammar-Carlemalm1, Johan Waldemarsson, Eskil Johnsson, Thomas Areschoug, Gunnar Lindahl.   

Abstract

Identification of antigens that elicit protective immunity is essential for effective vaccine development. We investigated the related surface proteins of group B Streptococcus, Rib and alpha, as potential vaccine candidates. Paradoxically, nonimmunodominant regions proved to be of particular interest as vaccine components. Mouse antibodies elicited by Rib and alpha were directed almost exclusively against the C-terminal repeats and not against the N-terminal regions. However, a fusion protein derived from the nonimmunodominant N-terminal regions of Rib and alpha was much more immunogenic than one derived from the repeats and was immunogenic even without adjuvant. Moreover, antibodies to the N-terminal fusion protein protected against infection and inhibited bacterial invasion of epithelial cells. Similarly, the N-terminal region of Streptococcus pyogenes M22 protein, which is targeted by opsonic antibodies, is nonimmunodominant. These data indicate that nonimmunodominant regions of bacterial antigens could be valuable for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078694     DOI: 10.1016/j.chom.2007.10.003

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  19 in total

1.  The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.

Authors:  Roland Schmitt; Anne-Lie Ståhl; Anders I Olin; Ann-Charlotte Kristoffersson; Johan Rebetz; Jan Novak; Gunnar Lindahl; Diana Karpman
Journal:  J Immunol       Date:  2014-05-21       Impact factor: 5.422

Review 2.  Genome-based approaches to vaccine development.

Authors:  Marirosa Mora; John L Telford
Journal:  J Mol Med (Berl)       Date:  2010-02       Impact factor: 4.599

3.  Streptococcus agalactiae alpha-like protein 1 possesses both cross-reacting and Alp1-specific epitopes.

Authors:  Augusta I Kvam; Rooyen T Mavenyengwa; Andreas Radtke; Johan A Maeland
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

Review 4.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

Review 5.  The role of vaccines in preventing bacterial antimicrobial resistance.

Authors:  Kathrin U Jansen; Charles Knirsch; Annaliesa S Anderson
Journal:  Nat Med       Date:  2018-01-09       Impact factor: 53.440

Review 6.  The nonideal coiled coil of M protein and its multifarious functions in pathogenesis.

Authors:  Partho Ghosh
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

7.  Novel epitopic region of glucosyltransferase B from Streptococcus mutans.

Authors:  Tomonori Hoshino; Yoshio Kondo; Kan Saito; Yutaka Terao; Nobuo Okahashi; Shigetada Kawabata; Taku Fujiwara
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 8.  Survey of immunological features of the alpha-like proteins of Streptococcus agalactiae.

Authors:  Johan A Maeland; Jan E Afset; Randi V Lyng; Andreas Radtke
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

Review 9.  Variation, Indispensability, and Masking in the M protein.

Authors:  Partho Ghosh
Journal:  Trends Microbiol       Date:  2017-08-31       Impact factor: 17.079

10.  Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017.

Authors:  Lesley McGee; Sopio Chochua; Zhongya Li; Saundra Mathis; Joy Rivers; Benjamin Metcalf; Alison Ryan; Nisha Alden; Monica M Farley; Lee H Harrison; Paula Snippes Vagnone; Ruth Lynfield; Chad Smelser; Alison Muse; Ann R Thomas; Stephanie Schrag; Bernard W Beall
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.